TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30326952

Group type: EXPERIMENTAL
Intervention: Monthly malaria prophylaxis (MMP) with dihydroartemisinin-piperaquine and weekly primaquine for 12 weeks
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Focused screening and treating (FSAT) following current Cambodian national treatment guidelines
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Permethrin-treated clothing
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Sham (water)-treated clothing
Number of subjects: 1000
Study: 27685606

Group type: EXPERIMENTAL
Intervention: Allergen inhalation challenge
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: IL‐25 stimulation in vitro
Number of subjects: 14

Group type: COMPARATOR
Intervention: Neutralizing IL‐25 antibody
Number of subjects: 14
Study: 23620250

Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Double‐jaw orthognathic surgery
Number of subjects: 45
Study: 22072378

Group type: EXPERIMENTAL
Intervention: 12 mg Astaxanthin (AXT) per day for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15765454

Group type: EXPERIMENTAL
Intervention: Continuous femoral and sciatic nerve blocks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous femoral nerve block
Number of subjects: 0
Study: 11889194

Group type: EXPERIMENTAL
Intervention: GLP-1 (1.2 pmol x kg(‐1) x min(‐1))
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: GLP-1
Number of subjects: 9

Group type: COMPARATOR
Intervention: NaCl (placebo)
Number of subjects: 9
Study: 9520605

Group type: EXPERIMENTAL
Intervention: Behavioral intervention (8-week program with mail materials and 6 structured telephone counseling sessions)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Educational intervention (single 5-minute telephone call and educational information)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 125
Study: 7866682

Group type: COMPARATOR
Intervention: CATEGO syndrome SD (subjective feelings of depression) during first admission
Number of subjects: 51

Group type: COMPARATOR
Intervention: CATEGO syndrome DD (depressive delusions)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Higher educational attainment
Number of subjects: 51

Group type: COMPARATOR
Intervention: CATEGO syndromes SD and OD (biological features of depression)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Female sex
Number of subjects: 51

Group type: COMPARATOR
Intervention: Occupational outcome
Number of subjects: 51
Study: 2491459

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 590301

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Practolol
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cyclothiazide
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 31075459

Group type: EXPERIMENTAL
Intervention: Decision aid intervention
Number of subjects: 178

Group type: COMPARATOR
Intervention: Control group (no decision aid)
Number of subjects: 178
Study: 29993130

Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone acetonide
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone acetonide with hyaluronidase
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intralesional verapamil hydrochloride
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intralesional radiofrequency
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intralesional radiofrequency with triamcinolone acetonide
Number of subjects: 100
Study: 27495295

Group type: EXPERIMENTAL
Intervention: Individually-tailored intervention promoting a Mediterranean-style dietary pattern and increased walking (Phase I)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Weight loss intervention (16 weekly group sessions or 5 group sessions and 10 phone calls) (Phase II)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Weight loss maintenance RCT (Phase III)
Number of subjects: 339
Study: 23893093

Group type: EXPERIMENTAL
Intervention: Raman spectroscopy
Number of subjects: 0
Study: 22374703

Group type: EXPERIMENTAL
Intervention: Preoperative crooked nose
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Postoperative straightening rhinoplasty
Number of subjects: 39

Group type: COMPARATOR
Intervention: Normal faces
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Decrease in nasal asymmetry by 1 point
Number of subjects: 39
Study: 20579205

Group type: EXPERIMENTAL
Intervention: Caregiver-oriented intervention programme
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 158
Study: 18375878

Group type: EXPERIMENTAL
Intervention: Home visiting program (8 visits by a trained home nurse over 18 months)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Control group (no home visits)
Number of subjects: 330
Study: 16045368

Group type: EXPERIMENTAL
Intervention: Culturally targeted self‐help nutrition and PA materials (Group 2)
Number of subjects: 1056

Group type: EXPERIMENTAL
Intervention: Culturally targeted self‐help nutrition and PA materials plus 4 telephone counseling calls based on motivational interviewing (MI) (Group 3)
Number of subjects: 1056

Group type: COMPARATOR
Intervention: Standard educational materials (Group 1)
Number of subjects: 1056
Study: 12164680

Group type: EXPERIMENTAL
Intervention: Isosceles triangular backgrounds (asymmetrically oriented with vertex in I visual field)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isosceles triangular backgrounds (fragments of the triangle)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Geometric illusions
Number of subjects: 0
Study: 10542973

Group type: EXPERIMENTAL
Intervention: Mometasone furoate dry powder inhaler (MF DPI) 100 mcg b.i.d.
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Mometasone furoate dry powder inhaler (MF DPI) 200 mcg b.i.d.
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Mometasone furoate dry powder inhaler (MF DPI) 400 mcg b.i.d.
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 168 mcg b.i.d.
Number of subjects: 365

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 365
Study: 7822648

Group type: EXPERIMENTAL
Intervention: Direct immunofluorescence staining
Number of subjects: 0

Group type: COMPARATOR
Intervention: Viral culture
Number of subjects: 0
Study: 2213870

Group type: EXPERIMENTAL
Intervention: Social-influence prevention program
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard care curricula
Number of subjects: 37
Study: 646474

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 31248026

Group type: EXPERIMENTAL
Intervention: Test formula (whey-based extensively hydrolyzed formula containing 2'fucosyl-lactose and lacto-N-neotetraose)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control formula (currently marketed extensively hydrolyzed formula without HMO)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Test formula
Number of subjects: 67
Study: 28300506

Group type: EXPERIMENTAL
Intervention: SOC + Cel (Celecoxib 400 mg twice a day for 1 year)
Number of subjects: 1245

Group type: EXPERIMENTAL
Intervention: SOC + ZA + Cel (Zoledronic acid 4 mg for six 3-weekly cycles, then 4-weekly for 2 years, plus Celecoxib 400 mg twice a day for 1 year)
Number of subjects: 1245

Group type: COMPARATOR
Intervention: SOC (Standard of care hormone therapy)
Number of subjects: 1245

Group type: EXPERIMENTAL
Intervention: SOC + ZA + Cel (in men with metastatic disease)
Number of subjects: 1245
Study: 25455832

Group type: EXPERIMENTAL
Intervention: Manual and manipulative therapy (MMT) alone
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Rehabilitation alone
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: MMT plus rehabilitation
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 83
Study: 23910762

Group type: EXPERIMENTAL
Intervention: TTM‐tailored print interventions
Number of subjects: 4178

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4178
Study: 20688590

Group type: EXPERIMENTAL
Intervention: Goldman tip procedure
Number of subjects: 100

Group type: COMPARATOR
Intervention: Suture technique
Number of subjects: 100
Study: 19830543

Group type: EXPERIMENTAL
Intervention: Half zona pellucida thinning
Number of subjects: 120

Group type: COMPARATOR
Intervention: Quarter zona pellucida thinning
Number of subjects: 120
Study: 16723326

Group type: EXPERIMENTAL
Intervention: Serial Response Time Task (SRTT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Artificial Grammar Learning (AGL)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Overall Implicit Learning
Number of subjects: 24
Study: 15337407

Group type: EXPERIMENTAL
Intervention: 10-day melarsoprol treatment
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Alternative treatment (10-day melarsoprol)
Number of subjects: 500
Study: 11177478

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied 3 times/week
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied once per day
Number of subjects: 64
Study: 9342777

Group type: COMPARATOR
Intervention: triazolam (0.25 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: capsule chosen (either placebo or triazolam)
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 7933683

Group type: EXPERIMENTAL
Intervention: 201Tl reinjection SPECT with sublingual nitroglycerin (NTG)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 201Tl reinjection SPECT without sublingual nitroglycerin (NTG)
Number of subjects: 80
Study: 3280125

Group type: EXPERIMENTAL
Intervention: Dietary supplementation with retinol, riboflavin, and zinc
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increase in retinol, riboflavin, and zinc blood levels
Number of subjects: 0
Study: 29174754

Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 26123704

Group type: EXPERIMENTAL
Intervention: CYP inhibition with ciprofloxacin, ketoconazole, and paroxetine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: CYP induction with rifampicin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Baseline (no pretreatment)
Number of subjects: 16
Study: 25916660

Group type: EXPERIMENTAL
Intervention: Dietary and exercise intervention
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 94
Study: 23616514

Group type: EXPERIMENTAL
Intervention: 1.0 g/d L-tryptophan
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 2.0 g/d L-tryptophan
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 3.0 g/d L-tryptophan
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 4.0 g/d L-tryptophan
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 5.0 g/d L-tryptophan
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (0 g/d)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: L-tryptophan (all doses)
Number of subjects: 17
Study: 20943066

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with monomeric allergoid (Lais, Lofarma) at three different maintenance doses
Number of subjects: 89

Group type: COMPARATOR
Intervention: Medications only (control group)
Number of subjects: 89
Study: 18548957

Group type: EXPERIMENTAL
Intervention: Mandibular dentures retained by 1 or 2 implants
Number of subjects: 220

Group type: COMPARATOR
Intervention: Screening process
Number of subjects: 220

Group type: COMPARATOR
Intervention: Reasons for exclusion
Number of subjects: 220

Group type: COMPARATOR
Intervention: Reasons for declining participation
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Reasons for agreeing to participate
Number of subjects: 220
Study: 16669406

Group type: EXPERIMENTAL
Intervention: Repetitive reactive hyperemia (T30, T60, T120)
Number of subjects: 20
Study: 12795787

Group type: EXPERIMENTAL
Intervention: Microsurgical access flap with enamel matrix derivative (EMD) application
Number of subjects: 11

Group type: COMPARATOR
Intervention: Microsurgical access flap alone (control)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Microsurgical access flap with EMD application
Number of subjects: 11
Study: 10650308

Group type: EXPERIMENTAL
Intervention: Phlebotomy
Number of subjects: 0
Study: 9715288

Group type: EXPERIMENTAL
Intervention: Medialisation osteotomy
Number of subjects: 138

Group type: COMPARATOR
Intervention: Anatomical reduction
Number of subjects: 138
Study: 1758327

Group type: EXPERIMENTAL
Intervention: Structured clinical teaching
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional bedside teaching
Number of subjects: 0
Study: 6857178

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) administration
Number of subjects: 8
Study: 30844467

Group type: EXPERIMENTAL
Intervention: FLASH education
Number of subjects: 216

Group type: COMPARATOR
Intervention: Control group (no FLASH education)
Number of subjects: 216
Study: 29428872

Group type: EXPERIMENTAL
Intervention: Ramipril treatment
Number of subjects: 0
Study: 27054838

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (LDA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25062965

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing Intervention (MI)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Self-Directed Intervention (C)
Number of subjects: 54
Study: 22067790

Group type: EXPERIMENTAL
Intervention: EE/drsp/levomefolate calcium
Number of subjects: 262

Group type: COMPARATOR
Intervention: EE/drsp
Number of subjects: 262
Study: 20850872

Group type: EXPERIMENTAL
Intervention: Healthy Families New York (HFNY) home visiting program
Number of subjects: 522

Group type: COMPARATOR
Intervention: Control group (referrals to other services)
Number of subjects: 522
Study: 17208410

Group type: EXPERIMENTAL
Intervention: VPA syrup (250mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: VPA capsule (250mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Divalproex sodium sprinkle capsule (250mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Divalproex sodium enteric-coated delayed-release tablet (250mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Divalproex sodium extended-release (divalproex-ER) tablet (250mg)
Number of subjects: 15
Study: 15223975

Group type: EXPERIMENTAL
Intervention: Modified management (M) with flexible glycemic targets based on ultrasound measurements of Abdominal Circumference (AC) centile.
Number of subjects: 229

Group type: COMPARATOR
Intervention: Conventional management (C) with fixed glycemic targets.
Number of subjects: 229
Study: 11454258

Group type: EXPERIMENTAL
Intervention: Plasmapheresis using Autopherese C
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Plasmapheresis using MCS3p
Number of subjects: 30
Study: 10068743

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg once daily
Number of subjects: 315

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 315
Study: 7518974

Group type: EXPERIMENTAL
Intervention: FK506
Number of subjects: 121

Group type: COMPARATOR
Intervention: CsA
Number of subjects: 121
Study: 2903874

Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (1.5 million units over 1 hour)
Number of subjects: 17187

Group type: EXPERIMENTAL
Intervention: Oral aspirin (160 mg/day for 1 month)
Number of subjects: 17187

Group type: EXPERIMENTAL
Intervention: Both streptokinase and aspirin
Number of subjects: 17187

Group type: EXPERIMENTAL
Intervention: Streptokinase alone
Number of subjects: 17187

Group type: EXPERIMENTAL
Intervention: Aspirin alone
Number of subjects: 17187

Group type: EXPERIMENTAL
Intervention: Combination of streptokinase and aspirin
Number of subjects: 17187

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 17187

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 17187

Group type: COMPARATOR
Intervention: Neither treatment
Number of subjects: 17187
Study: 8314481

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (5 MU three times a week for 8 weeks, then 3 MU three times a week for 7 months)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b
Number of subjects: 48

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 48
Study: 631642

Group type: EXPERIMENTAL
Intervention: Adrenaline infusion at 0.12 microgram/min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adrenaline infusion at 0.25 microgram/min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adrenaline infusion at 4 microgram/min
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adrenaline infusion (various doses)
Number of subjects: 0
Study: 31094267

Group type: EXPERIMENTAL
Intervention: 1073R-1-yogurt (100g every morning for 12 weeks)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control yogurt (different Lactobacillus strain)
Number of subjects: 96
Study: 28844118

Group type: EXPERIMENTAL
Intervention: MDCO-216 (5-40 mg/kg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: MDCO-216
Number of subjects: 48

Group type: COMPARATOR
Intervention: ETC-216
Number of subjects: 48

Group type: COMPARATOR
Intervention: MDCO-216 vs ETC-216
Number of subjects: 48
Study: 25805397

Group type: EXPERIMENTAL
Intervention: Soyabean oil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sunflower oil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Soyabean oil vs. Sunflower oil
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both intervention arms
Number of subjects: 60
Study: 23644901

Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 16

Group type: COMPARATOR
Intervention: No CPAP therapy (Control)
Number of subjects: 16
Study: 21093107

Group type: EXPERIMENTAL
Intervention: Written handout added to verbal explanation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Verbal explanation only (Control)
Number of subjects: 50
Study: 19470987

Group type: EXPERIMENTAL
Intervention: Optimized antidepressant therapy followed by a pain self-management program (12 weeks of therapy + 6 sessions of self-management over 12 weeks + 6 months continuation)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Optimized antidepressant therapy followed by a pain self-management program
Number of subjects: 250
Study: 17566453

Group type: EXPERIMENTAL
Intervention: Supervised circuit strength-training program (n=57)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Unsupervised standard conditioning program (n=26)
Number of subjects: 83
Study: 15502599

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 to 60 mg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11258693

Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 175
Study: 9754891

Group type: COMPARATOR
Intervention: Traditional basilic vein transposition (Group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Staged basilic vein transposition (Group B)
Number of subjects: 40
Study: 8118531

Group type: EXPERIMENTAL
Intervention: Out-of-hospital delivery
Number of subjects: 59
Study: 3367174

Group type: EXPERIMENTAL
Intervention: Geriatric evaluation unit (GEU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 31438903

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention delivered over 17 weeks alongside enhanced usual care.
Number of subjects: 899

Group type: COMPARATOR
Intervention: Enhanced usual care (control arm).
Number of subjects: 899
Study: 27255431

Group type: EXPERIMENTAL
Intervention: GL + sita (sitagliptin + insulin glargine)
Number of subjects: 65

Group type: COMPARATOR
Intervention: NOV (premixed insulin aspart 30)
Number of subjects: 65
Study: 25448109

Group type: EXPERIMENTAL
Intervention: Full-dose IPV intramuscularly with needle and syringe
Number of subjects: 981

Group type: EXPERIMENTAL
Intervention: fIPV intradermally administered with one of two new injectors
Number of subjects: 981

Group type: EXPERIMENTAL
Intervention: fIPV administered with BCG needle
Number of subjects: 981

Group type: EXPERIMENTAL
Intervention: fIPV administered with a conventional needle-free injector
Number of subjects: 981

Group type: EXPERIMENTAL
Intervention: One of the two new injectors
Number of subjects: 981

Group type: EXPERIMENTAL
Intervention: Other new injector
Number of subjects: 981
Study: 23777741

Group type: EXPERIMENTAL
Intervention: Axillary radiotherapy
Number of subjects: 285

Group type: COMPARATOR
Intervention: No axillary radiotherapy
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Axillary radiotherapy and No axillary radiotherapy (regardless of arm)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: HER2-positive and triple-negative subtypes
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: High Ki67 cancers (≥14%)
Number of subjects: 285
Study: 21829907

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral group therapy combined with pharmacotherapy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Pharmacotherapy alone
Number of subjects: 41
Study: 19571281

Group type: EXPERIMENTAL
Intervention: Combined PET-CT
Number of subjects: 189

Group type: COMPARATOR
Intervention: Conventional staging
Number of subjects: 189
Study: 16909131

Group type: EXPERIMENTAL
Intervention: sc‐IL‐2, sc‐IFN‐alpha2a, po‐13cRA (Arm A)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: sc‐IL‐2, sc‐IFN‐alpha2a, po‐13cRA + inhaled‐IL‐2 (Arm B)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: sc‐IL‐2, sc‐IFN‐alpha2a, po‐13cRA + iv‐5‐FU (Arm C)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: sc‐IL‐2, sc‐IFN‐alpha2a, po‐13cRA + po‐Capecitabine (Arm D)
Number of subjects: 379

Group type: COMPARATOR
Intervention: Comparison between Arm A and Arm B
Number of subjects: 379

Group type: COMPARATOR
Intervention: Comparison between Arm C and Arm D
Number of subjects: 379
Study: 15261564

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide plus beta interferon
Number of subjects: 225

Group type: COMPARATOR
Intervention: Beta interferon alone
Number of subjects: 225
Study: 11302007

Group type: EXPERIMENTAL
Intervention: 10 g fish powder
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (20 tablets/day)
Number of subjects: 0
Study: 8841501

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 31